Current controversy exists over whether PI-2620 tracer may exhibit a more favorable binding affinity profile to 4-repeat tau aggregates in PSP and CBD in comparison to Flortaucipir and MK-6240. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.